System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Clinical Trial, Phase III Ppublish

PubMed: 42852816 DOI: 10.1111/cts.70737

Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.

Clin Transl Sci 19(10):e70737

Authors: Philip H Li, F Ida Hsu, Emel Aygören-Pürsün, William R Lumry, Jason Raasch, Ingo Pragst, Yinglei Li, Chiara Nenci, Marco Campioni, Markus Magerl

Affiliations

  • Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
  • Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • University Hospital Frankfurt, Department for Children and Adolescents, Goethe University Frankfurt, Frankfurt, Germany.
  • AARA Research Center, Dallas, Texas, USA.
  • Midwest Immunology Clinic, Plymouth, Minnesota, USA.
  • CSL Innovation GmbH, Marburg, Germany.
  • CSL Behring, King of Prussia, Pennsylvania, USA.
  • CSL Behring AG, Bern, Switzerland.
  • CSL Vifor Pharma Management Ltd. Zurich, Switzerland.
  • Charité - University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Institute of Allergology, Berlin, Germany.
  • Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.

Abstract

Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life-threatening. Across the clinical program, garadacimab long-term prophylaxis demonstrated early onset and durable, sustained protection against HAE attacks and clinically meaningful improvements in health-related quality of life (HRQoL). HAE treatment goals include total disease control (attack-free) and normalization of life. Predicting treatment effect may aid shared decision-making and choice of long-term prophylaxis. Here, we report an attack-free probability model predicting garadacimab treatment effect beyond available Phase 3 clinical data and explore the relationship between HRQoL and attack-free duration. A generalized mixed-effect Poisson model was developed and validated with data from the garadacimab pivotal Phase 3 (VANGUARD) and Phase 3 open-label extension studies. Efficacy variables, including attack-free probabilities, were predicted for simulated populations of garadacimab-treated patients and assessed for goodness of fit. Analysis of covariance was used to assess the relationship between Angioedema Quality of Life questionnaire scores and attack-free duration. Model-predicted efficacy variables adequately reflected observed clinical data with high goodness of fit (Nakagawa-Schielzeth conditional R 2: 74.3%). Following a 1-month attack-free period after garadacimab initiation, patients had a 60% cumulative probability of remaining attack-free up to Month 25 and 49% up to 5 years. HRQoL improved with increasing duration of attack-free periods, reaching minimal to no impairment after 6 months. This attack-free probability model suggests long-term effects of garadacimab over a 5-year treatment period. Patients treated with garadacimab have the potential to live attack-free for long periods of time, with substantial HRQoL improvements.

MeSH

Quality Of Life, Biomedical Research, Probability, Angioedemas, Hereditary, Antibodies, Monoclonal, Therapeutics, Angioedema